Trial Profile
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Avitinib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 05 Nov 2021 Results published in the Clinical Cancer Research
- 02 Sep 2021 Planned End Date changed from 1 Dec 2020 to 1 Mar 2023.
- 02 Sep 2021 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.